Table 2.
Utility values and costing data considered in the model
| Parameters | Values | Source |
|---|---|---|
| Utility values | ||
| No hospitalization | SHIFT trial | |
| NYHA I | 0.82 | |
| NYHA II | 0.74 | |
| NYHA III | 0.64 | |
| NYHA IV | 0.46 | |
| Hospitalization | SHIFT trial | |
| NYHA I | −0.04 | |
| NYHA II | −0.07 | |
| NYHA III | −0.10 | |
| NYHA IV | −0.29 | |
| Drug costs per month | price bulletin issued by the Greek Ministry of Health [15], law 4052/2012, Government Gazette | |
| Standard care | €35.26 | |
| Ivabradine | €40.52 | |
| Other therapy related costs | ||
| ECG | €3.44 | |
| Hospitalization cost (cost per diem) | Government Gazzette, Ministerial Desicion 104494, 26/9/2011 | |
| Intensive Care Unit | €200 | |
| Cardiac Units | €110 | |
| Other resource use | Government Gazzette [16] and local experts’ opinion | |
| On-going HF management costs | €26.05 |
HF: Heart Failure; ECG: electrocardiographic changes; NYHA: New York Heart Association.